116 related articles for article (PubMed ID: 21740293)
21. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors.
Porta C; Figlin RA
J Urol; 2009 Dec; 182(6):2569-77. PubMed ID: 19836781
[TBL] [Abstract][Full Text] [Related]
22. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
23. Targeting the Met pathway in lung cancer.
Belalcazar A; Azaña D; Perez CA; Raez LE; Santos ES
Expert Rev Anticancer Ther; 2012 Apr; 12(4):519-28. PubMed ID: 22500688
[TBL] [Abstract][Full Text] [Related]
24. Constitutive c-Met signaling through a nonautocrine mechanism promotes metastasis in a transgenic transplantation model.
Yu Y; Merlino G
Cancer Res; 2002 May; 62(10):2951-6. PubMed ID: 12019177
[TBL] [Abstract][Full Text] [Related]
25. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
Ma PC; Schaefer E; Christensen JG; Salgia R
Clin Cancer Res; 2005 Mar; 11(6):2312-9. PubMed ID: 15788682
[TBL] [Abstract][Full Text] [Related]
26. The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis.
You WK; McDonald DM
BMB Rep; 2008 Dec; 41(12):833-9. PubMed ID: 19123972
[TBL] [Abstract][Full Text] [Related]
27. Novel therapeutic target for head and neck squamous cell carcinoma: HGF-MET signaling pathway.
Lau PC; Chan AT
Anticancer Drugs; 2011 Aug; 22(7):665-73. PubMed ID: 21709616
[TBL] [Abstract][Full Text] [Related]
28. Investigational MET inhibitors to treat Renal cell carcinoma.
Nandagopal L; Sonpavde GP; Agarwal N
Expert Opin Investig Drugs; 2019 Oct; 28(10):851-860. PubMed ID: 31554440
[No Abstract] [Full Text] [Related]
29. Targeting the c-MET signaling pathway for cancer therapy.
Liu X; Yao W; Newton RC; Scherle PA
Expert Opin Investig Drugs; 2008 Jul; 17(7):997-1011. PubMed ID: 18549337
[TBL] [Abstract][Full Text] [Related]
30. Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors.
Haddad R; Lipson KE; Webb CP
Anticancer Res; 2001; 21(6B):4243-52. PubMed ID: 11908677
[TBL] [Abstract][Full Text] [Related]
31. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
Zivi A; Cerbone L; Recine F; Sternberg CN
Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
[TBL] [Abstract][Full Text] [Related]
32. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
[TBL] [Abstract][Full Text] [Related]
33. Resistance to angiogenesis inhibitors in renal cell carcinoma.
Tamaskar I; Dhillon J; Pili R
Clin Adv Hematol Oncol; 2011 Feb; 9(2):101-10. PubMed ID: 22173604
[TBL] [Abstract][Full Text] [Related]
34. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic evaluation of cabozantinib for the treatment of thyroid cancer.
Karras S; Pontikides N; Krassas GE
Expert Opin Drug Metab Toxicol; 2013 Apr; 9(4):507-15. PubMed ID: 23488614
[TBL] [Abstract][Full Text] [Related]
36. Role of c-mesenchymal-epithelial transition pathway in gastric cancer.
Fioroni I; Dell'Aquila E; Pantano F; Intagliata S; Caricato M; Vincenzi B; Coppola R; Santini D; Tonini G
Expert Opin Pharmacother; 2015 Jun; 16(8):1195-207. PubMed ID: 25881479
[TBL] [Abstract][Full Text] [Related]
37. C-MET as a potential target therapy toward personalized therapy in some pediatric tumors: An overview.
Rashed WM
Crit Rev Oncol Hematol; 2018 Nov; 131():7-15. PubMed ID: 30293708
[TBL] [Abstract][Full Text] [Related]
38. MET: a promising anticancer therapeutic target.
Peters S; Adjei AA
Nat Rev Clin Oncol; 2012 May; 9(6):314-26. PubMed ID: 22566105
[TBL] [Abstract][Full Text] [Related]
39. c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy.
Mohan CD; Shanmugam MK; Gowda SGS; Chinnathambi A; Rangappa KS; Sethi G
Phytomedicine; 2024 Jun; 128():155379. PubMed ID: 38503157
[TBL] [Abstract][Full Text] [Related]
40. C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas.
Marona P; Górka J; Kotlinowski J; Majka M; Jura J; Miekus K
Cells; 2019 Mar; 8(3):. PubMed ID: 30909397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
